
2 min Read Feb 1, 2025
Voltas shares drop 13% after disappointing Q3 results

2 min Read Feb 1, 2025

Wockhardt shares gained 10% after the company announced that its flagship discovery product, Zaynich, achieved 96.8% efficacy in a phase III study for complicated urinary...
By Ventura Research Team








